CHINMOY K BOSE MD, PhD, DSc.
Also known as: Chinmay K Basu
SAGE Publishing (United States), BMC Cancer, University of Burdwan, University of Calcutta, CDSCO, Vivekananda Institute of Medical Sciences
About
I was a national science talent search scholar in my school leaving examination. Throughout my academic journey of MBBS, DGO and MD in gynecology and oncology, research had been first choice. I pursued my own original research on ovarian cancer etiology and drug development since my PhD through many international awards and fellowships, and my DSc degree spanning more than two decades. Excepting for a few stints of general gynecology service for city living, I dedicated myself to continuing research and super specialty career recognized by the ASCO and the AACR. My knack for publication, fifteen years of editorial attachment in a Springer-Nature journal, involvement in global clinical trials and in drug development and my long association with the Indian drug regulatory body dealing with hundreds of dossiers of clinical trial approval, drug approval and marketing authorization applications have been instrumental in creating my huge interest in reviewing analysing and deciding on manuscripts and projects.
Employment
-
SAGE Publishing (United States) Associate editor2023 - Present
-
BMC Cancer Editorial board member2022 - Present
-
CDSCO Subject Expert2018 - Present
-
National Board of Examinations Paper And Practical examiner, Medical Oncology2017 - Present
-
Journal of Medical case Reports Deputy editor2016 - Present
-
Central Drugs Standard Control Organization Member, Subject Expert Committee, oncology and haematoncology.2014 - Present
-
Netaji Subhas Chandra Bose Cancer Research Institute Honorary Consultant2007 - Present
-
J N Roy Hospital Consultant2005 - Present
Education
-
University of Burdwan DSc2012 - 2023
-
University of Calcutta PhD1989 - 1995
-
Vivekananda Institute of Medical Sciences MD1985 - 1989
-
R. G. Kar Medical College and Hospital MBBS1974 - 1979
Projects & Funding
Projects & funding information is unavailable.
Publications (28)
- A Review of Bispecific T-cell Engagers (BiTEs): A Promising Strategy in the Evolving Landscape of Cancer Immunotherapy Save
- Sacituzumab Tirumotecan in the Evolving Landscape of Ovarian Cancer Treatment Save
- Tumor-Resident Bacteria: Mechanisms of Carcinogenesis, Metastasis and Clinical Implications Save
- Irreversible Electroporation in Ovarian Cancer: A Comprehensive Review of Therapeutic and Research Applications Save
- Volrustomig Save
- Bispecific immunotherapy MEDI5752 or volrustomig and cervical cancer Save
- Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy Save
- Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer Save
- Immune Checkpoint Inhibitors (ICI) in Advanced and Recurrent Endometrial Cancer Save
- Inhibitory role of a smart nano-trifattyglyceride of Moringa oleifera root in epithelial ovarian cancer, through attenuation of FSHR - c-Myc axis Save